Analysts initiate coverage on Alumis and Enliven with bullish ratings

benzinga.com

Baird analyst Brian Skorney has started coverage on Alumis Inc. with an Outperform rating and a price target of $25. The stock closed at $11.23 on Wednesday. Jones Trading analyst Soumit Roy also initiated coverage on Enliven Therapeutics with a Buy rating and a price target of $36, while the stock closed at $28.39. Other analysts began coverage on Intensity Therapeutics, Terns Pharmaceuticals, and Braze, with varying ratings and price targets reflecting their current stock prices.


With a significance score of 3.4, this news ranks in the top 8.4% of today's 21581 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 10,000+ subscribers:


Analysts initiate coverage on Alumis and Enliven with bullish ratings | News Minimalist